Sorry, Internet Explorer and the old Edge Versions are not supported...
Please use an up-to-date Firefox, Chrome, Opera or the new Chromium based Edge to visit this website.

⚠️ You are using an old version of Edge. ⚠️

This browser can not support the full functionality of this website. For a better user experience we recommend to use the latest version of Edge or other up-to-date Browsers like Firefox, Chrome or Opera...

Pathologic Speech Processing

Currently in the US, 42% of Americans have a family member with Alzheimer’s.

Pathologic Speech Processing

Currently in the US, 42% of Americans have a family member with Alzheimer’s.

Screenshot of the current data collection application running on an iPad

If you spot the early signs of Alzheimer's and Dementia it is easier to create a personal care pathway. Yet half of Americans suffering from Alzheimer's are not diagnosed.

PSP does just that. It is a detection system of a number of tasks that spots early signs of Alzheimer’s through a speech recognition system. Speech allows self-indication of neurodegenerative diseases, earlier than often recognized by a doctor.

If you spot the early signs of Alzheimer's and Dementia it is easier to create a personal care pathway. Yet half of Americans suffering from Alzheimer's are not diagnosed.

PSP does just that. It is a detection system of a number of tasks that spots early signs of Alzheimer’s through a speech recognition system. Speech allows self-indication of neurodegenerative diseases, earlier than often recognized by a doctor.

Screenshot of the current data collection application running on an iPad

Having the patient’s needs in the center of innovative digital developments and addressing true unmet medical needs, that characterizes the mindset in our initiative. What we develop is an easy to use system with artificial intelligence that is trained to identify pathological speech and language patterns indicative for mental and neurodegenerative diseases. The system will ease the access of patients to the medical system and support physicians in making a diagnosis. This scientific work aims to become a validated cornerstone for digital biomarkers in the future.

Dr. Christoph Eschenfelder - Product Owner of PSP

Having the patient’s needs in the center of innovative digital developments and addressing true unmet medical needs, that characterizes the mindset in our initiative. What we develop is an easy to use system with artificial intelligence that is trained to identify pathological speech and language patterns indicative for mental and neurodegenerative diseases. The system will ease the access of patients to the medical system and support physicians in making a diagnosis. This scientific work aims to become a validated cornerstone for digital biomarkers in the future.

Dr. Christoph Eschenfelder - Product Owner of PSP

Currently PSP is in its first steps of evaluation in a proof of concept study in academic memory clinics.

PSP spots standard biomarkers like Impaired articulation, word-finding difficulties, impaired reading comprehension, lack of attention and comprehension thanks to the built-in Artifical Intelligence based on the state-of-the-art in natural language processing and machine learning, which will alert patients and Health Care Providers to the early onset of Alzheimer’s and other mental illnesses in the future.

Currently PSP is in its first steps of evaluation in a proof of concept study in academic memory clinics.

PSP spots standard biomarkers like Impaired articulation, word-finding difficulties, impaired reading comprehension, lack of attention and comprehension thanks to the built-in Artifical Intelligence based on the state-of-the-art in natural language processing and machine learning, which will alert patients and Health Care Providers to the early onset of Alzheimer’s and other mental illnesses in the future.

Inside BI X GmbH
© 2020 BI X GmbH All rights reserved
A Boehringer Ingelheim company | Binger Strasse 173, 55216 Ingelheim / Rhein, Germany